Abstract

Background

Metabolic syndrome (MetS) refers to clustered cardiovascular risk factors (abdominal obesity, pre-diabetes, high blood pressure, dyslipidaemia). Therapies targeting oxidative stress may delay progression to atherosclerosis and diabetes. We investigated the anti-oxidative effect of a supplement combining red yeast rice and olive extract in patients with MetS.

Methods

A double-blind, placebo-controlled, randomised trial was conducted with 50 patients with MetS as defined by National Cholesterol Education Program Adult Treatment Panel III criteria. Forty-nine subjects randomly assigned to red yeast rice-olive extract (RYR-olive extract; 10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per Cholesfytolplus capsule) or placebo completed the 8-week trial. Whereas effects on cardiovascular risk parameters of MetS have been reported recently, the observed significant 20% increase in oxidised low-density lipoprotein (OxLDL) prompted us to investigate other oxidative stress-related parameters: malondialdehyde (MDA), lipoprotein-associated phospholipase A2 (Lp-PLA2) and 8-hydroxy-2′-deoxyguanosine (8-OHdG). Statistical calculations included univariate quantitative analysis, multivariate linear regression and correlation analysis.

Results

The updated results indicate that an RYR-olive extract supplement significantly reduced Lp-PLA2 by 7% (p < 0.001), but it failed to show a significant decrease in plasma MDA and 8-OHdG (p > 0.05). Reductions in OxLDL (20%) and Lp-PLA2 (7%) were associated with each other (r = 0.740, p < 0.001).

Conclusions

RYR-olive extract significantly reduced Lp-PLA2 in correlation with the marked reduction in plasma OxLDL, which may lead to a reduced risk for cardiovascular disease in patients with MetS.

Trial registration

ClinicalTrials.gov identifier: NCT02065180. Registered on 13 February 2014.

Details

Title
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial
Author
Hermans, Nina 1   VIAFID ORCID Logo  ; Van der Auwera, Anastasia 1 ; Breynaert, Annelies 1 ; Verlaet, Annelies 1 ; De Bruyne, Tess 1 ; Van Gaal, Luc 2 ; Pieters, Luc 1 ; Verhoeven, Veronique 3 

1  University of Antwerp, Natural Products and Food - Research & Analysis (NatuRA), Department of Pharmaceutical Sciences, Antwerp, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681) 
2  Antwerp University Hospital, Department of Endocrinology, Diabetology and Metabolism, Edegem, Belgium (GRID:grid.411414.5) (ISNI:0000 0004 0626 3418) 
3  University of Antwerp, The academic centre for primary and interdisciplinary care, Faculty of Medicine and Health Sciences, Antwerp, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681) 
Pages
302
Publication year
2017
Publication date
Dec 2017
Publisher
Springer Nature B.V.
e-ISSN
17456215
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s13063-017-2058-5
ProQuest document ID
2795253271
Copyright
© The Author(s). 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.